IL-10 Inhibits FcεRI Expression in Mouse Mast Cells
Author(s) -
Sheila R. Gillespie,
Randall R. DeMartino,
Jingfang Zhu,
Hey Chong,
Carlos Ramírez,
Christopher P. Shelburne,
L. Andrew Bouton,
Daniel P. Bailey,
Anita Gharse,
Paria Mirmonsef,
Sandra Odom,
Gregorio Gomez,
Juan Rivera,
Krista FischerStenger,
John Ryan
Publication year - 2004
Publication title -
the journal of immunology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.172.5.3181
Subject(s) - cytokine , microbiology and biotechnology , immunoglobulin e , receptor , mast cell , effector , biology , cytokine receptor , chemistry , immunology , antibody , biochemistry
FcepsilonRI expression and function is a central aspect of allergic disease. Using bone marrow-derived mouse mast cell populations, we have previously shown that the Th2 cytokine IL-4 inhibits FcepsilonRI expression and function. In the current study we show that the Th2 cytokine IL-10 has similar regulatory properties, and that it augments the inhibitory effects of IL-4. FcepsilonRI down-regulation was functionally significant, as it diminished inflammatory cytokine production and IgE-mediated FcepsilonRI up-regulation. IL-10 and IL-4 reduced FcepsilonRI beta protein expression without altering the alpha or gamma subunits. The ability of IL-4 and IL-10 to alter FcepsilonRI expression by targeting the beta-chain, a critical receptor subunit known to modulate receptor expression and signaling, suggests the presence of a Th2 cytokine-mediated homeostatic network that could serve to both initiate and limit mast cell effector function.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom